A meta-analysis of biologics for ABPA treatment enrolled 86 studies involving 346 patients and demonstrated that omalizumab, dupilumab, and mepolizumab could significantly lower the exacerbation rate and total serum IgE levels, while benralizumab showed a similar trend but did not reach statistical significance ( 29 ).
← all excerpts
Relapsing allergic bronchopulmonary aspergillosis as a trigger for Kounis syndrome: a case report.
1
—
—